Diagnostic Approach for Dermatomyositis with Normal Creatine Kinase

Initial Laboratory Testing

The American College of Rheumatology recommends measuring aldolase, LDH, AST, and ALT, as these can be elevated even when CK is normal 1, 2, 3
Inflammatory markers (ESR and CRP) are essential for both diagnosis and monitoring, according to the European League Against Rheumatism 1, 2, 3
Troponin levels must be checked to evaluate for potentially life-threatening myocardial involvement, as suggested by the American Heart Association 1, 2, 3

A thorough skin examination for Gottron's papules, heliotrope rash, V-sign, shawl sign, and cutaneous ulcers is recommended by the American Academy of Dermatology 1, 2, 3
Muscle strength testing with emphasis on proximal muscle groups is crucial, as muscle weakness is more typical than pain in myositis, according to the American College of Rheumatology 1, 2, 3
Assessment for dysphagia and respiratory muscle involvement is necessary, as it indicates more severe disease, as stated by the European Respiratory Society 4

MRI of proximal limbs can reveal inflammatory changes even when muscle enzymes are normal, and is more sensitive than ultrasound, according to the American College of Radiology 1, 2, 3
Electromyography (EMG) may demonstrate myopathic changes despite normal CK levels, as suggested by the American Association of Neuromuscular and Electrodiagnostic Medicine 1, 2, 3
Muscle biopsy should be considered when diagnosis is uncertain, as it can show inflammatory myopathy even with normal CK, according to the American College of Rheumatology 1, 2, 3

Troponin, ECG, and echocardiogram should be obtained if there is any clinical suspicion of myocardial involvement, as recommended by the American Heart Association 1, 2, 3, 4
Cardiac involvement represents a medical emergency and would require permanent discontinuation of any causative agents, according to the American College of Cardiology 3, 5

Serial monitoring should include CK, ESR, and CRP for disease activity tracking, as suggested by the European League Against Rheumatism 1, 2, 3, 4
Muscle strength assessments are necessary to evaluate treatment response, according to the American College of Rheumatology 4
Malignancy screening is appropriate for age and risk factors, given the paraneoplastic association, as recommended by the American Cancer Society 1